Psilocybin-Assisted Therapy Delivers Lasting Mental Health Benefits for Cancer Patients
A single 25 mg dose of psilocybin, combined with structured psychological support, may offer a promising alternative to traditional antidepressants for cancer patients with major depressive disorder. In a 24-month follow-up study, 53.6% of participants maintained significant reductions in depression, while 50% achieved sustained remission. Anxiety symptoms also improved, with 46.4% experiencing long-term relief. Notably, 25% of patients sustained depression improvement without additional antidepressants, psychedelic treatments, or depression-related hospitalizations. These findings highlight the potential of psilocybin-assisted therapy as a durable and transformative approach for managing cancer-related depression and anxiety.
Psilocybin-Assisted Therapy Delivers Lasting Mental Health Benefits for Cancer Patients Read More »










